GSK has received Canadian approval for Arexvy, its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making...
Pfizer's experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing severe infections in infants when given to expecting mothers in the second...